This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamamoto, M. Articles by Ogata, E. Search for Related Content PubMed PubMed Citation Articles by Yamamoto, M. Articles by Ogata, E. Pubmed/NCBI databases OMIM Compound via MeSH Substance via MeSH Hazardous Substances DB 1,25-DIHYDROXYCHOLECALCIFEROL CALCIUM COMPOUNDS CALCIUM, ELEMENTAL PARATHYROID HORMONE

Comparison of Hypocalcemic Hypercalciuria between Patients with Idiopathic Hypoparathyroidism and Those with Gain-of-Function Mutations in the Calcium-Sensing Receptor: Is It Possible to Differentiate the Two Disorders?

Third Department of Internal Medicine (M.Y.) and Department of General Medicine (T.A.), National Defense Medical College, Saitama 359-8513; Self-Defense Force Central Hospital (T.N.), Tokyo 154-8532; and Cancer Institute Hospital (E.O.), Tokyo 170-8455, Japan

Address all correspondence and requests for reprints to: Michiko Yamamoto, M.D., Third Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.

Gain-of-function mutations in the calcium ion-sensing receptor (CaR) cause hypocalcemia with low PTH levels. It is stated that patients with activating CaR mutations generally show milder degree of hypocalcemia before treatment and more profound hypercalciuria during treatment than those with idiopathic hypoparathyroidism (IHP). To test this validity we analyzed the data of serum and urinary calcium collected from 85 patients with IHP and 15 with activating CaR mutations. The mean (±SEM) serum calcium concentration before treatment was significantly higher (P < 0.001) in patients with activating CaR mutations (1.76 ± 0.05 mmol/L; n = 15) than in those with IHP (1.41 ± 0.03; n = 58), but there was a substantial overlap in the range of hypocalcemia between the two groups (1.25–2.05 vs. 0.90–1.95). The mean urinary calcium/creatinine ratio (Ca/Cr) in patients with activating CaR mutations before treatment (0.362 ± 0.045 mmol/mmol; n = 9) was almost equal to that in normocalcemic controls (0.331 ± 0.022; n = 56) and markedly higher (P < 0.001) than in patients with IHP (0.093 ± 0.008; n = 57). The overlap of pretreatment urinary Ca/Cr between the 2 disorders was relatively small; subnormal urinary Ca/Cr was observed in only 1 of 9 patients with CaR mutations and in the majority (49 of 57) of patients with IHP. In contrast to pretreatment findings, the degree of hypercalciuria during treatment was not different between the 2 disorders. The data points of urinary Ca/Cr plotted as a function of the serum calcium concentration were not separable between patients with CaR mutations (n = 8) and those with IHP (n = 40). Comparison of urinary Ca/Cr between 2 patients with a CaR mutation and 7 with IHP over a wide range of serum calcium concentrations measured during 4–8 yr of treatment also indicated that the 2 disorders were inseparable. These results suggested that inappropriately normal urinary Ca/Cr in patients with untreated hypocalcemia, mostly of mild degree, might be a better biochemical clue than the development of severe hypercalciuria during treatment to suspect gain-of-function mutations in the CaR.

This article has been cited by other articles:

				D. Shoback Hypoparathyroidism N. Engl. J. Med., July 24, 2008; 359(4): 391 - 403. [Full Text] [PDF]

				T. A. Hough, D. Bogani, M. T. Cheeseman, J. Favor, M. A. Nesbit, R. V. Thakker, and M. F. Lyon Activating calcium-sensing receptor mutation in the mouse is associated with cataracts and ectopic calcification PNAS, September 14, 2004; 101(37): 13566 - 13571. [Abstract] [Full Text] [PDF]

				P. Houillier and M. Paillard Calcium-sensing receptor and renal cation handling Nephrol. Dial. Transplant., December 1, 2003; 18(12): 2467 - 2470. [Full Text] [PDF]

				J Singh, N Moghal, S H S Pearce, and T Cheetham The investigation of hypocalcaemia and rickets Arch. Dis. Child., May 1, 2003; 88(5): 403 - 407. [Abstract] [Full Text] [PDF]

				K. Sato, Y. Hasegawa, J. Nakae, K. Nanao, I. Takahashi, T. Tajima, N. Shinohara, and K. Fujieda Hydrochlorothiazide Effectively Reduces Urinary Calcium Excretion in Two Japanese Patients with Gain-of-Function Mutations of the Calcium-Sensing Receptor Gene J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3068 - 3073. [Abstract] [Full Text] [PDF]

				T. Nagase, T. Murakami, T. Tsukada, R. Kitamura, N. Chikatsu, H. Takeo, N. Takata, H. Yasuda, S. Fukumoto, Y. Tanaka, et al. A Family of Autosomal Dominant Hypocalcemia with a Positive Correlation between Serum Calcium and Magnesium: Identification of a Novel Gain of Function Mutation (Ser820Phe) in the Calcium-Sensing Receptor J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2681 - 2687. [Abstract] [Full Text] [PDF]

				J. Barber, R. C. Butler, M. W. J. Davie, and C. A. Sewry Hypoparathyroidism presenting as myopathy with raised creatine kinase Rheumatology, December 1, 2001; 40(12): 1417 - 1418. [Full Text] [PDF]

				A. Lienhardt, M. Bai, J.-P. Lagarde, M. Rigaud, Z. Zhang, Y. Jiang, M.-L. Kottler, E. M. Brown, and M. Garabedian Activating Mutations of the Calcium-Sensing Receptor: Management of Hypocalcemia J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5313 - 5323. [Abstract] [Full Text] [PDF]